News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medsite's E-Pharma Marketing Gain Share Methodology Increases WellSpring Pharmaceutical Corporation's Dyrenium Prescriptions; Medsite Pharmaceutical Services Offers A Zero Cost, Zero Risk Option For Mature Therapies With Limited Marketing Resources


10/19/2005 5:12:26 PM

Medsite Pharmaceutical Services LLC, a new division of Medsite, today announced the results from its initial pilot gain share program with the WellSpring Pharmaceutical Corporation. After six months of Phase I promotion for Dyrenium100mg(R), a 40-year-old diuretic therapy, a target group, representing 15 percent of Dyrenium prescribing physicians, generated a 40 percent increase in new prescriptions written. These results were established by a promotional evaluation study conducted by IMS Management Consulting Services.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES